NAME OF THE MEDICINE: isotretinoin

Structurally it is represented as:

![Chemical Structure of Isotretinoin]

Isotretinoin, C_{20}H_{28}O_{2}. CAS 4759-48-2.

DESCRIPTION

Isotretinoin is 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-cis-(4,6,8)-trans-nonatetraenoic acid (also known as 13-cis-retinoic acid). MW: 300.44 g/mol. Isotretinoin is related to both retinoic acid and retinol (Vitamin A). Isotretinoin is a yellow - orange to orange crystalline powder that is practically insoluble in water, soluble in methylene chloride, sparingly soluble in ether and slightly soluble in alcohol. It is sensitive to air, heat and light, especially in solution.

Oratane® capsules contain Isotretinoin, Beeswax – yellow, Disodium edetate, Butylated Hydroxyanisole, dl-alpha-tocopherol, Soya oil – partially hydrogenated, Soya oil, Vegetable oil – hydrogenated (5mg, 10mg and 20mg only), Soya oil – hydrogenated (40mg only).

The capsule shell contains Sorbitol solution (70% non-crystallising), Glycerol, Gelatin, Titanium dioxide, Water – purified, Brilliant scarlet 4R CI16255 (10mg and 20mg only), Sunset yellow FCF CI15985 (40mg only), Indigo carmine CI73015 (20mg only), Iron oxide black CI177499 (10mg only).

PHARMACOLOGY

Pharmacodynamics

Oratane® contains isotretinoin; this is a retinoid that inhibits sebaceous gland function and keratinisation. The exact mechanism of action of isotretinoin is unknown.

Clinical improvement in cystic acne patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is reversible and the extent is related to the dose and duration of treatment with Oratane® and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation.

PHARMACOKINETICS

Absorption

There is considerable interindividual variation in the bioavailability of oral isotretinoin. After oral administration of 80 mg isotretinoin (2 x 40 mg capsules) given in the fasting state, peak plasma concentrations ranged from 167 to 459 nanogram/mL and mean time to peak was 3.2 hours in healthy volunteers, while in acne patients peak concentrations ranged from 98 to 535 nanogram/mL (mean 262 nanogram/mL) with a mean time to peak of 2.9 hours.

The bioavailability of isotretinoin capsules taken with food is 1½ to 2 times greater than when taken in a fasting state.
**Distribution**

*Tissue distribution in animals:* Tissue distribution of $^{14}$C-isotretinoin in rats revealed high concentrations of radioactivity in many tissues after 15 minutes, with a maximum in 1 hour and declining to nondetectable levels by 24 hours in most tissues. After seven days, however, low levels of radioactivity were detected in the liver, ureter, adrenal, ovary and lacrimal gland.

The drug is 99.9% bound in human plasma almost exclusively to albumin.

**Metabolism**

The major identified metabolite in blood and urine is 4-oxo-isotretinoin. Tretinoin and 4-oxo-tretinoin were also observed. After two 40 mg capsules of isotretinoin, maximum concentrations of the metabolite of 87 to 399 nanogram/mL occurred at 6 to 20 hours. The blood concentration of the major metabolite generally exceeded that of isotretinoin after 6 hours.

The mean ± SD minimum steady state blood concentrations of isotretinoin were 160 ± 19 nanogram/mL in ten patients receiving 40 mg twice daily. After single and multiple doses, the mean ratio of areas under the curves of isotretinoin to 4-oxo-isotretinoin is 3 to 3.5.

**Elimination**

The terminal elimination half-life of isotretinoin ranged from 10 to 20 hours in volunteers and patients. Following an 80 mg liquid suspension oral dose of $^{14}$C-isotretinoin, $^{14}$C activity in blood declined with a half-life of 90 hours. Relatively equal amounts of radioactivity were recovered in the urine and faeces with 65 to 83% of the dose recovered. The apparent half-life for elimination of the 4-oxo-metabolite ranged from 11 to 50 hours with a mean of 29 hours. This metabolite is subject to recycling in the enterohepatic circulation.

**INDICATIONS**

Oratane® is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. If a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. Because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

**CONTRAINDICATIONS**

*Use in pregnancy (Category X)*

Australian categorisation definition of Category X:

Drugs which have such a high risk of causing permanent damage to the foetus that they should not be used in pregnancy of when there is a possibility of pregnancy.

Isotretinoin is highly teratogenic and should not be used during pregnancy.

Isotretinoin must not be used by females who are pregnant or who may possibly become pregnant while undergoing treatment.

Major human foetal abnormalities related to isotretinoin administration have been reported, including hydrocephalus, microcephalus, abnormalities of the external ear (micropinna, small or absent external auditory canals), eye abnormalities (including microphthalmia), cardiovascular abnormalities (conotruncal malformations such as tetralogy of Fallot, transposition of great vessels, septal defects), facial dysmorphism, cleft palate, thymus gland abnormality, parathyroid gland abnormalities and cerebellar malformation/abnormalities. There is also an increased incidence of spontaneous abortion.

Women of childbearing potential should not be given isotretinoin until pregnancy is excluded. It is strongly recommended that a pregnancy test be performed within two weeks prior to isotretinoin therapy. Isotretinoin therapy should start on the second or third day of the next normal menstrual period. An effective form of contraception should be used for at least one month before and also throughout isotretinoin therapy.
It is recommended that contraception be continued for one month following discontinuation of Oratane® therapy. Females should be fully counselled on the serious risk to the foetus should they become pregnant while undergoing treatment. If pregnancy does occur during treatment, the physician and patient should discuss the desirability of continuing the pregnancy.

Oratane® is contraindicated in patients who are breast-feeding (see PRECAUTIONS – Use in Lactation).

Oratane® is contraindicated in patients with severely impaired liver function and in patients with chronic abnormally elevated blood lipid values.

Oratane® is also contraindicated in people who are hypersensitive to the drug or other ingredients in Oratane® capsules or to other retinoids.

Oratane® is contraindicated in patients who have pre-existing hypervitaminosis A.

Rare cases of benign intracranial hypertension have been reported after isotretinoin and after tetracyclines. Concomitant treatment with tetracyclines is therefore contraindicated (see also PRECAUTIONS: Interactions with other Medicines).

PRECAUTIONS

Information for Patients
Women of childbearing potential should be warned that the drug causes birth defects. They should be instructed that they must not be pregnant when isotretinoin therapy is initiated, and that they should use an effective form of contraception while taking isotretinoin and for one month after isotretinoin has been stopped (see CONTRAINDICATIONS).

Because of the relationship of isotretinoin to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects.

Oratane® contains soya oil, therefore caution should be taken with patients allergic to peanut or soya.

Donation of blood by patients during and within one month of cessation of isotretinoin treatment to women of childbearing potential should be avoided.

Skin and Subcutaneous Tissue Disorders
Acute exacerbation of acne is generally seen during the initial period of treatment; but this subsides with continued treatment, usually within 7-10 days, and usually does not require dose adjustments.

Wax epilation should be avoided in patients on Oratane® and for a period of 5-6 months after treatment because of the risk of epidermal stripping, scarring or dermatitis.

Aggressive chemical dermabrasion and cutaneous laser treatment should be avoided in patients on Oratane® and for a period of 5-6 months after the end of treatment because of risk of hypertrophic scarring in atypical areas and more rarely hyper- or hypo-pigmentation in treated areas.

Exposure to intense sunlight or UV rays should be avoided. Where necessary, a sun protection product with a high protection factor of at least SPF 15 should be used.

Patients should be advised to use a skin-moisturising ointment or cream and a lip balm from the start of treatment as Oratane® is likely to cause dryness of the skin and lips.

There have been post-marketing reports of severe skin reactions (eg. erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis) associated with isotretinoin use. These events may be serious and result in death, life threatening events, hospitalisation or disability. Patients should be monitored closely for severe skin reactions and discontinuation of Oratane® should be considered if warranted.
**Benign Intracranial Hypertension**

Isotretinoin use has been associated with a number of cases of benign intracranial hypertension (pseudotumour cerebri), some of which involved the concomitant use of tetracyclines. Early signs and symptoms of benign intracranial hypertension include papilloedema, headache, nausea and vomiting, and visual disturbances. Patients who develop benign intracranial hypertension should discontinue Oratane immediately.

**Eye Disorders**

Dry eyes, corneal opacities, conjunctivitis, blepharitis, decreased night vision and keratitis usually resolve after discontinuation of therapy. Dry eyes can be helped by the application of a lubricating eye ointment or by the application of tear replacement therapy. Due to the possible occurrence of keratitis, patients with dry eyes should be monitored. Patients experiencing visual difficulties should be referred for an expert ophthalmological examination and withdrawal of isotretinoin considered. Intolerance to contact lenses may occur which may necessitate the patient to wear glasses during treatment.

Corneal opacities have occurred in patients receiving isotretinoin for acne and more frequently when higher drug dosages were used in patients with disorders of keratinisation. All Oratane patients experiencing visual difficulties should discontinue the drug and have an ophthalmological examination.

**Hearing Impairment**

Impaired hearing has been reported in patients taking Isotretinoin. Hearing impairment can be unilateral or bilateral, and symptoms include tinnitus, impaired hearing at certain frequencies and deafness. In some cases, hearing impairment has been reported to persist after therapy has been discontinued. Anyone who experiences these symptoms should immediately seek medical advice; the drug should be ceased and the patient should undergo urgent formal audiology assessment.

**Biochemical Abnormalities**

Rises in alanine and aspartate aminotransferases enzymes (ALT and AST) have been reported. **Liver function tests, especially AST and blood lipids, should be measured before therapy and at monthly intervals during therapy and at the end of treatment.** When transaminase levels exceed the normal levels, reduction of dose or discontinuation of treatment may be necessary.

Isotretinoin causes elevation of serum triglycerides and cholesterol as well as a decrease in high-density lipoprotein (HDL) which appear to be related to duration of treatment and are reversible on cessation of treatment. The degree of elevation may also be dose dependent, although this has not been conclusively established.

At doses of greater than 1 mg/kg/day, approximately one in four patients have been found to develop elevated triglycerides while taking isotretinoin. At lower doses triglyceride levels elevated above the normal range are uncommon.

Some patients have been able to reverse triglyceride elevations by weight reduction and restriction of dietary fat and alcohol while continuing to take isotretinoin. Serum lipid values usually return to normal on reduction of dose or discontinuation of treatment.

Acute pancreatitis, which is potentially fatal, sometimes associated with serum triglyceride levels > 8 g/L, has been reported. Hence, Oratane should be discontinued if uncontrolled hypertriglyceridemia or symptoms of pancreatitis occur.

Serum lipid (fasting value) should be determined one month prior to therapy and again about 4 weeks of therapy and subsequently at three month intervals unless more frequent monitoring is clinically indicated.

Predisposing factors such as a family history of lipid metabolism disorders, obesity, alcohol abuse, diabetes and smoking should be assessed. In high risk patients (with diabetes, obesity, alcoholism or lipid metabolism disorder) undergoing treatment with Oratane®, more frequent checks of serum values for lipids and/or blood glucose may be necessary.
Musculo-skeletal and Connective Tissue Disorders
Myalgia, arthralgia and increased serum creatine phosphokinase may occur and may be associated with reduced tolerance to vigorous exercise (see ADVERSE EFFECTS).

In clinical trials of disorders of keratinisation with a mean dose of 2.24 mg/kg/day, a high prevalence of skeletal hyperostosis was noted. Bone changes including premature epiphyseal closure and calcifications of tendons and ligaments have occurred after administration of high doses for long periods for treating disorders of keratinisation. The dose levels, duration of treatment and total cumulative dose in these patients generally far exceeded those recommended for the treatment of acne.

Minimal skeletal hyperostosis has also been observed by X-rays in prospective studies of nodular acne patients treated with a single course of therapy at recommended doses.

Due to the possible occurrence of these bone changes, a careful evaluation of the risk/benefit ratio should be carried out in every patient and isotretinoin administration should be restricted to severe cases.

Hepatobiliary Disorders
Several cases of clinical hepatitis have been noted which are considered to be possibly or probably related to isotretinoin therapy. Additionally, mild to moderate elevations of liver enzymes have been observed in approximately 15% of individuals treated during clinical trials, some of which normalised with dosage reduction or continued administration of the drug. If normalisation does not readily occur or if hepatitis is suspected during treatment with isotretinoin, the drug should be discontinued and the etiology further investigated.

Psychiatric Disorders
Depression, psychotic symptoms, and, rarely, suicide, suicidal ideation and attempts have been reported with isotretinoin. Particular care needs to be taken in patients with a history of depression and all patients should be monitored for signs of depression. Although no mechanism of action for these events has been established, discontinuation of Oratane® may not alleviate symptoms and therefore further psychiatric or psychological evaluation may be necessary.

Gastrointestinal Disorders
Isotretinoin has been associated with inflammatory bowel disease (including regional ileitis) in patients without a prior history of intestinal disorders. Patients experiencing abdominal pain, rectal bleeding or severe (hemorrhagic) diarrhoea should discontinue isotretinoin immediately.

Allergic Reactions
Anaphylactic reactions have been reported rarely and only after previous topical exposure to retinoids. Allergic cutaneous reactions are reported infrequently. Serious cases of allergic vasculitis, often with purpura (bruises and red patches) of the extremities and extracutaneous involvement have been reported. Severe allergic reactions necessitate interruption of therapy and careful monitoring.

Renal Insufficiency
Renal insufficiency and renal failure do not affect the pharmacokinetics of isotretinoin. Therefore, isotretinoin can be given to patients with renal insufficiency. Isotretinoin should be started at a lower dose in patients with severe renal insufficiency and afterwards dose adjusted according to tolerance.

Effects on Ability to Drive or Operate Machinery
Decreased night vision has occurred during isotretinoin therapy and in rare instances has persisted after discontinuation of therapy. As the onset in some patients was sudden, patients should be advised of this potential problem and warned to be cautious when driving or operating any vehicle at night.

Carcinogenicity and Genotoxicity
In Fischer 344 rats given isotretinoin at dosages of 32 or 8 mg/kg/day for greater than 18 months, there was dose related increased incidence of pheochromocytoma. The incidence of adrenal medullary hyperplasia was also increased at the higher dosage. There is doubt as to the validity of this animal model as a predictor of tumorigenicity in humans, as the Fischer rat is genetically predisposed to the multiple Endocrine Neoplasia Syndrome which includes spontaneous occurrence of pheochromocytoma. In these
studies there was also a dose related decrease in the incidence of liver adenomata, liver angiomata and leukaemia.

Isotretinoin was negative in tests for gene mutation (histidine reversion in *S. typhimurium*), chromosomal damage *in vitro* (Chinese hamster lung cell and *S. cervisiae* D7 assays) and *in vivo* (Mouse micronucleus test), and unscheduled DNA synthesis *in vitro* (rat hepatocytes)

**Effects on Fertility**

In the reproductive studies in rats (2, 8 or 32 mg/kg/day; 2-generation), no adverse effects were noted on gonadal function, fertility, gestation or neonatal viability, although the average weight in the high dose group was slightly reduced.

In dogs, testicular atrophy was noted after treatment with isotretinoin for approximately 30 weeks at dosages of 60 or 20 mg/kg/day. In general, there was microscopic evidence for appreciable depression of spermatogenesis, but some sperm were observed in all testes examined and in no instance were completely atrophic tubules seen. In studies in 66 human males, 30 of whom were patients with cystic acne, no significant changes were noted in the count or motility of spermatozoa in the ejaculate.

**Use in Pregnancy:** Pregnancy Category X

Australian categorisation definition of Category X:

Drugs which have such a high risk of causing permanent damage to the fetus that they should not be used in pregnancy if there is a possibility of pregnancy.

Isotretinoin is a known human teratogen and should not, under any circumstances, be administered during pregnancy (see Contraindications).

Isotretinoin should only be prescribed by physicians who are experienced in the use of systemic retinoids and understand the risk of teratogenicity.

Isotretinoin is teratogenic in rats and rabbits although sensitivity differs. In the rat, doses up to 50 mg/kg/day were not teratogenic but 150 mg/kg/day was teratogenic. At lower doses in the rat perinatal and post-natal studies (5, 15, 32 mg/kg/day) increased pup mortality was noted in all treatment groups. This was attributed to a dose-related reduction in maternal food intake. Body weight development of pups was significantly impaired in high dose groups.

In the rabbit, a dose of 10 mg/kg/day caused abortions in 9 out of 13 animals and teratogenicity and embryotoxicity were observed in the remaining 4 litters.

**Use in Lactation**

As isotretinoin is highly lipophilic, the passage of the drug in human milk is very likely. Because of the potential for adverse effects, the use of isotretinoin is contraindicated in breast-feeding mothers.

**Paediatric Use**

The approved therapeutic indication does not involve use in children and safety in pre-pubertal children has not been established (see also PRECAUTIONS, Hyperostosis).

**Effects on Laboratory Tests**

Elevation of lipid (triglycerides and cholesterol) levels occurs with isotretinoin therapy. These are usually mild in doses less than 1 mg/kg/day and elevations above the normal range are unusual at 0.5 mg/kg/day. At doses above 1 mg/kg/day, elevation (above normal range) occurs in 25% of patients.

These changes are seen more frequently in patients where a family history of lipid disorders, or obesity, alcohol abuse, diabetes mellitus or smoking is present. The changes are dose related and may be controlled by dietary means (including alcohol restriction) or dosage reduction (see also PRECAUTIONS: Biochemical abnormalities).

Elevated ESR values occur in about 40% of patients treated with isotretinoin.
A rise in aspartate aminotransferase (AST) levels may occur, especially with higher doses of isotretinoin. Although the changes have usually been within the normal range, and may return to baseline levels despite continued treatment, significant increases have occurred in a few cases, necessitating dosage reduction or discontinuation of isotretinoin.

Certain patients receiving isotretinoin have experienced problems in the control of their blood sugar. Therefore, known or suspected diabetics should have frequent blood sugar determinations performed during isotretinoin therapy. New cases of diabetes have been diagnosed.

A small number of patients have shown proteinuria, microscopic or gross hematuria and elevated CPK.

**INTERACTIONS WITH OTHER MEDICINES**

As a rule concomitant therapy is not indicated but non-irritant topical preparations may be used if required. Concurrent administration of isotretinoin with topical keratolytic or exfoliative anti-acne agents should be avoided as local irritation may increase.

Concurrent treatment with vitamin A must be avoided, as symptoms of hypervitaminosis A may be intensified (see **ADVERSE EFFECTS**).

Cases of pseudotumour cerebri and/or papilloedema have been reported in association with the use of isotretinoin. Four out of ten of these patients had retinal haemorrhages. Symptoms appeared after 21 days to 6 months therapy with 40 to 120 mg daily. Concomitant tetracycline or minocycline was administered in 5 out of 10 cases—both of these drugs have been implicated in causing intracranial hypertension. Concomitant therapy with tetracyclines is contraindicated (see under **CONTRAINDICATIONS**).

Since acne is an androgen-dependent disease, contraceptives containing an androgen progestational substance, such as one derived from 19-nortestosterone (norsteroid), particularly in the presence of gynaeco-endocrinological problems, should be avoided.

The effect of microdosed progesterone preparations may be diminished by interaction with isotretinoin. Therefore, micro-dosed progesterone preparations or “minipills” should not be used.

**ADVERSE EFFECTS**

Most adverse effects appear to be dose related with the more pronounced effects occurring at doses above 1 mg/kg/day. The adverse effects may recede during continued therapy and the mucocutaneous effects were reversible with dosage reduction or discontinuation of therapy. Exacerbation of the cystic acne may occur during the initial stages of therapy.

Many of the adverse effects seen in patients receiving isotretinoin are similar to those described in patients taking very high doses of vitamin A.

**Post-Marketing Experience**

*Symptoms associated with hypervitaminosis A*

The most common side effects are mucocutaneous. The most frequently reported effects are dryness of the skin, in particular peeling of the palms and soles, dryness of the mucosa e.g. lips (cheilits which occurs in over 90% of patients), the nasal mucosa (epistaxis is seen in up to 30% of patients), the pharynx (hoarseness) and eyes (conjunctivitis, reversible corneal opacities and intolerance to contact lenses).

*Skin and appendages disorders*

Exanthena, pruritis, facial erythema/dermatitis, sweating, pyogenic granuloma, paronychia, nail dystrophy, increased formation of granulation tissue, persistent hair thinning, reversible alopecia, acne fulminans, hirsutism, hyperpigmentation, photosensitivity, photoallergic effects, skin fragility. Acne flare occurs at start of treatment and persists for several weeks.
During the post-marketing period, erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported with isotretinoin (see PRECAUTIONS).

**Musculoskeletal system disorders**

Myalgia (muscle pain) with or without elevated serum CPK values (see PRECAUTIONS), arthralgia (joint pain), tenderness or stiffness of bones, hyperostosis, arthritis, calcification of ligaments and tendons and other bone changes, reduced bone density, back pain, epiphsyes, premature fusion, tendinitis.

Serious cases of rhabdomyolysis, often leading to hospitalisation and some with fatal outcome have been reported, particularly in those undertaking vigorous physical activity.

**Psychiatric and Central Nervous System Disorders**

Behavioural disorders, depression, suicide attempt, suicide (see PRECAUTIONS), headache, increased intracranial pressure (pseudotumour cerebri), and seizures.

**Sensory Disorders**

Visual disturbances, photophobia, decreased night vision, colour vision disturbances (reversible upon discontinuation), lenticular cataracts, keratitis, blurred vision, blepharitis, conjunctivitis, eye irritation, papilledema as a sign of benign intracranial hypertension, impaired hearing at certain frequencies.

**Gastrointestinal System Disorders**

Nausea, severe diarrhoea, inflammatory bowel disease such as colitis, ileitis and haemorrhage has been reported to occur. Patients on isotretinoin, especially those with high triglyceride levels, are at risk of developing pancreatitis. Fatal pancreatitis has been rarely reported (see PRECAUTIONS).

**Liver and Biliary System Disorders**

Transient and reversible increases in liver transaminases, some cases of hepatitis.

**Respiratory System Disorders**

Bronchospasm has been rarely reported; sometimes in patients with a pre-history of asthma.

**Disorders of the Blood**

Decrease in white blood cell count, neutropenia, disorders of red blood cell parameters (such as decrease in red blood cell count and haematocrit), elevation of sedimentation rate increase or decrease in platelet count (thrombocytopenia) and anaemia.

**Laboratory Findings**

Increase in serum triglyceride and cholesterol levels, decrease in HDL, hyperuricemia. Rare cases of elevated blood glucose have been reported, and new cases of diabetes have been diagnosed (see PRECAUTIONS).

**Resistance Mechanism Disorders**

Local or systemic infections due to Gram positive microorganisms (Staphylococcus aureus).

**Miscellaneous Reactions**

Decreases in haematocrit, lymphadenopathy, haematuria, and proteinuria, vasculitis (for example Wegener’s granulomatosis, allergic vasculitis), allergic responses, systemic hypersensitivity, and glomerulonephritis.

**DOSAGE AND ADMINISTRATION**

The therapeutic response to isotretinoin is dose related and varies between patients. This necessitates individual adjustment of dosage according to the response of the condition and the patient’s tolerance of the drug. In most cases complete or near complete suppression of acne is achieved with a 16 week course of treatment.

All patients should initially receive doses up to 0.5 mg/kg bodyweight daily for a period of two to four weeks, when their responsiveness to the drug will usually be apparent. It should be noted that the transient
exacerbation of acne is occasionally seen during this initial period. Satisfactory initial responses have been reported from 0.05 mg/kg/day. Relapse rates on the lower doses are higher (a second course may be required in about two-thirds of patients on 0.1 mg/kg/day for 16 weeks), but there is decreased incidence and severity of adverse effects at lower doses.

The daily dosage should be taken with food in the nearest number of whole capsules, either as a single dose or in two divided doses during the day, whichever is more convenient.

Doses up to 1 mg/kg/day may be used in patients refractory to initial treatment at lower doses.

The above daily dosages of isotretinoin should be continued for 16 weeks to complete the course of treatment.

After a period of two months off therapy, and if warranted by persistent severe cystic acne, a second course of therapy may be initiated.

OVERDOSAGE

Signs of hypervitaminosis A could appear in cases of overdose. Clinically, overdose has been associated with transient headache, vomiting, facial flushing, cheilosis, abdominal pain, headache, dizziness and ataxia. All symptoms quickly resolved without apparent residual effects.

Treatment of overdose should consist of general supportive measures.

Immediately telephone your doctor, or National Poisons Information Centre (Phone 13 11 26) for advice, or go to your nearest Casualty Department (Accident and Emergency Centre) if you think that you or anyone else may have received/taken too much Oratane®.

PRESENTATION AND STORAGE CONDITIONS

Oratane® 5 mg capsules are soft, oval, faint pinkish/cream to cream in colour containing a yellow/orange liquid. They are available in PVC/PVDC/Al blister packs of 15 (sample pack)*, 30*, 60 and 90* capsules.

Oratane® 10 mg capsules are light violet coloured soft gelatin capsules containing a yellow/orange viscous liquid. They are available in PVC/PVDC/Al blister packs of 15 (sample pack)*, 30*, 60 and 90* capsules.

Oratane® 20 mg capsules are maroon coloured soft gelatin capsules containing a yellow/orange viscous liquid. They are available in PVC/PVDC/Al blister packs of 15 (sample pack)*, 30*, 60 and 90* capsules.

Oratane® 40 mg capsules are orange coloured soft gelatin capsules containing a yellow/orange viscous liquid. They are available in PVC/PVDC/Al or PVC/PCTFE/Al blister packs of 15 (sample pack)*, 30, 60* and 90* capsules.

Store below 30°C in the closed carton to protect from light and moisture:

- ORATANE® 20 mg capsules AUST R 69868

Store below 25°C in the closed carton to protect from light and moisture:

- ORATANE® 5 mg capsules AUST R 127499
- ORATANE® 10 mg capsules AUST R 75034
- ORATANE® 40 mg capsules AUST R 117206

* currently not marketed

POISONS SCHEDULE
Schedule 4 – Prescription Only Medicine
NAME AND ADDRESS OF THE SPONSOR

Douglas Pharmaceuticals Australia Pty Ltd
15 – 17 Chapel Street
Cremorne Victoria 3121

Distributed by Arrow Pharmaceuticals Pty Ltd on behalf of Oraderm Pharmaceuticals Pty Ltd
15 – 17 Chapel Street
Cremorne Victoria 3121

Date of first inclusion on the Australian Register of Therapeutic Goods (the ARTG): 16 August 1999

Date of most recent amendment: 26th August 2016